Journal of Huntington's Disease

Impact Factor
2024
2.1
CiteScore
2024
4.8

Volume

13, 4 issues

Latest issue

13:2 online 05 July 2024

Next issue

13:3 scheduled for October 2024

Back volumes

From volume 1, 2012

ISSN print

1879-6397

ISSN online

1879-6400

Aims & Scope

The Journal of Huntington's Disease is an international multidisciplinary journal to facilitate progress in understanding the genetics, molecular correlates, pathogenesis, pharmacology, diagnosis and treatment of Huntington's disease and related disorders. The journal publishes research reports, reviews, short communications, letters-to-the-editor, and will consider research that has negative findings. The journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that will expedite our fundamental understanding and improve treatment of Huntington's disease and related disorders.

Editorial Board

Editors-in-Chief

Blair R. Leavitt, MD
The University of British Columbia
Vancouver, BC
Canada
Email: b.leavitt@iospress.com

Leslie M. Thompson, PhD
University of California
Irvine, CA
USA
Email: l.thompson@iospress.com

Editor for Reviews

Marian DiFiglia
Massachusetts General Hospital Charlestown, Boston
USA

Associate Editors for Reviews

Flaviano Giorgini
University of Leicester, Leicester
United Kingdom

Ai Yamamoto, Columbia University, New York
USA

Associate Editor for Clinical Trials Corner

Edward Wild
UCL Institute of Neurology, London
United Kingdom

Associate Editors

Karen E. Anderson
MedStar Georgetown University Hospital & Georgetown University Medical Center, Washington
USA

Neil Aronin, University of Massachusetts Medical School, Worcester
USA

Lu Boxun
School of Life Sciences, Fudan University, Shanghai
China

Carlos Cepeda
David Geffen School of Medicine at University of California Los Angeles
Los Angeles, CA, USA

Jang-Ho Cha
Latus Biosciences
Cambridge, MA, USA
    
David Craufurd
The University of Manchester, Manchester
United Kingdom
    
Alexandra Durr
Université Pierre et Marie Curie, Paris
France
    
Lisa M. Ellerby
Buck Institute for Research on Aging, Novato
USA
    
Samuel Frank
Beth Israel Deaconess Medical Center, Boston
USA
    
Anthony Hannan
The University of Melbourne, Victoria
Australia

Jun Hua
Department of Radiology and Radiological Science
Johns Hopkins University, Baltimore, MD, USA

Kimberly B. Kegel-Gleason
Massachusetts General Hospital East, Charlestown, MA
USA
    
Doug Langbehn
University of Iowa Hospital & Clinic, Iowa
USA
    
Michael Levine
University of California, Los Angeles
USA
    
Cynthia McMurray
Lawrence Berkeley National Laboratory, Life Sciences Division, Berkeley
USA

Tiago Mestre 
Ottawa Hospital Research Institute, Ottawa
Canada
    
Martha A. Nance
Struthers Parkinson's Center, Golden Valley
USA

Huu Phuc Nguyen
Ruhr-University Bochum, Bochum
Germany

Peggy C. Nopoulos
Department of Psychiatry
University of Iowa Carver College of Medicine
Iowa City, IA, USA

Asa Petersen
Lund University, Lund
Sweden
    
Mahmoud A. Pouladi
Department of Medical Genetics
The University of British Columbia
Vancouver, BC, Canada
    
Lori Quinn
Department of Biobehavioral Studies, Teachers College, Columbia University, New York
USA
    
Lynn Raymond
University of British Columbia, Vancouver
Canada
    
Ralf Reilmann
George-Huntington-Institute, Münster, University of Münster, University of Tübingen
Germany
    
Christopher A. Ross
Johns Hopkins University, Baltimore
USA
    
Carsten Saft
St. Josef Hospital, Bochum
Germany
    
Frédéric Saudou
Institut Curie, Paris
France
    
Julie Stout
Monash University, Victoria
Australia
    
Sarah Tabrizi
University College London, London
United Kingdom

X. William Yang
David Geffen School of Medicine at UCLA, Los Angeles, CA
USA

Anne B. Young
Massachusetts General Hospital, Boston
USA
    
Scott O. Zeitlin
University of Virginia School of Medicine, Charlottesville
USA

Social Media Editor

Tamara Maiuri
McMaster University, Hamilton
Canada

Managing Editor

Bethany Kumar
Case Western Reserve University, Cleveland
USA
Email: jhd@iospress.com

Editorial Board

Nick Allen
Cardiff School of Biosciences, Cardiff
United Kingdom

Roger A. Barker
University of Cambridge, Cambridge
United Kingdom

Gillian P. Bates
Kings College London, London
United Kingdom

Ilya Bezprozvanny
University of Texas Southwestern Medical School, Dallas
USA

Kevin M. Biglan
University of Rochester Medical Center, Rochester
USA

Juan Botas
Baylor College of Medicine, Houston
USA

Patrik Brundin
Van Andel Research Institute, Grand Rapids
USA

Josep M. Canals
University of Barcelona, Barcelona
Spain

Jeff Carroll
Western Washington University, Bellingham
USA
    
Elena Cattaneo
Universita degli Studi di Milano, Milan
Italy
    
Marie-Francoise Chesselet
University of California, Los Angeles
USA
    
Jody Corey-Bloom
University of California, San Diego
USA
    
Merit Cudkowicz
Massachusetts General Hospital, Boston
USA
    
Beverly Davidson
The University of Iowa, Iowa City
USA

Ray Dorsey
University of Rochester Medical Center, Rochester
USA

Wenzhen Duan
Johns Hopkins University, Baltimore, USA
New Zealand

Richard Faull
University of Auckland, Grafton
New Zealand

Andrew Feigin
NYU Langone Health, New York
USA

Joaquim Ferreira
Instituto de Farmacologia e Terapêutica Geral, Lisbon
Portugal

Steven Finkbeiner
University of California, San Francisco
USA

Nellie Georgiou-Karistianis
Monash University, Victoria
Australia

Michelle Gray
The University of Alabama at Birmingham, Birmingham
USA

James F. Gusella
Massachusetts General Hospital, Boston
USA
    
Mark Guttman
Centre for Movement Disorders, Toronto
Canada

Michael Hayden
Centre for Molecular Medicine and Therapeutics, Vancouver
Canada

Steven M. Hersch
Massachusetts General Hospital, Boston
USA

David E. Housman
Koch Institute at MIT, Cambridge
USA

Carl D. Johnson
Hereditary Disease Foundation, Broadway
USA

Aleksey G. Kazantsev
National Institutes of Health, Bethesda, MD
USA

Manho Kim
Seoul National University Hospital, Seoul National University College of Medicine, Seoul
South Korea

Ron R. Kopito
Stanford University School of Medicine, Stanford
USA

Dimitri Krainc
Northwestern University, Chicago
USA

G. Bernhard Landwehrmeyer
Universitätsklinik Ulm, Ulm
Germany

Albert La Spada
University of California, San Diego
USA

Ruth Luthi-Carter
University of Leicester, Leicester
United Kingdom

Marcy MacDonald
Massachusetts General Hospital, Boston
USA

J. Lawrence Marsh
University of California, Irvine
USA

Wayne Martin
University of Alberta, Edmonton
Canada

Mark Mattson
NIA, NIH, Bethesda
USA

Diane Merry
Thomas Jefferson University, Pennsylvania
USA

Anne Messer
University of Albany, New York
USA

Gerardo Morfini
University of Illinois at Chicago, Chicago
USA
    
Jenny Morton
University of Cambridge, Cambridge
United Kingdom

Richard H. Myers
Boston University, Boston
USA

Peg Nopoulos
University of Iowa Carver College of Medicine, Iowa City
USA

Nobuyuki Nukina
Doshisha University Graduate School of Brain Science, Kyoto
Japan

Jane S. Paulsen
University of Iowa, Iowa City
USA

Henry Paulson
University of Michigan Health System, Ann Arbor
USA

Anna C. Pfalzer
Vanderbilt University Medical Center, Nashville
USA

Ricardo Mouro Pinto
Massachusetts General Hospital, Harvard Medical School
Boston, USA

Oliver Quarrell
Sheffield Clinical Genetics Department, Sheffield Children's Hospital, Sheffield
United Kingdom

Laura Ranum
University of Florida, Gainesville
USA

Raj Ratan
Burke Rehabilitation Hospital, White Plains
USA

Anton Reiner
The University of Tennessee Health Science Center, Memphis
USA

Eric Reits
University of Amsterdam, Amsterdam
The Netherlands

Raymund Roos
Leiden University Medical Center, Leiden
The Netherlands

Diana Rosas
Massachusetts General Hospital, Boston
USA

Adam Rosenblatt
Virginia Commonwealth University Medical Center, Richmond
USA

Anne Rosser
Cardiff University, Cardiff
United Kingdom

Ira Shoulson
Georgetown University, Washington DC
USA

Andrew Singleton
NIH, Bethesda
USA

Amber L. Southwell
University of Central Florida, Orlando
USA

Ferdinando Squitieri
IRCCS Casa Sollievo della Sofferenza Hospital and LIRH Foundation, Rome
Italy

Joan S. Steffan
University of California, Irvine
USA

Erin Furr Stimming
University of Texas Health Science Center, Houston
USA

Victor Sung
University of Alabama, Birmingham
USA

Jean-Paul Vonsattel
Columbia University, New York
USA

Judith R. Walters
NIH, Bethesda
USA

Erich Wanker
Max Delbrueck Center for Molecular Medicine, Berlin
Germany

Alice Wexler
University of California, Los Angeles
USA

Nancy Wexler
Columbia University, New York
USA

Vanessa Wheeler
Massachusetts General Hospital, Boston
USA

George Yohrling
Huntington's Disease Society of America, New York
USA

Author Guidelines

SUBMISSION OF MANUSCRIPT

PLEASE SUBMIT YOUR MANUSCRIPT HERE.

SUBMISSION POLICY

By submitting my article to this journal, I agree to the Author Copyright Agreement, the IOS Press Ethics Policy, and the IOS Press Privacy Policy.

Submission of an article is understood to imply that the article is original and unpublished and is not being considered for publication elsewhere. Any possible conflict of interest, financial or otherwise, related to the submitted work must be clearly indicated in the manuscript.

The article type (Research paper, Review paper, Editorial, Case Report, Letter to the Editor, etc) should be clearly mentioned in the cover letter to help the editorial process.

This journal operates with single-blind peer review. If the author prefers double-blind peer review, then please submit the manuscript excluding the author listing and make sure the document is anonymized, and list the authors and affiliations only in the cover letter for the Editor.

The manuscript and accompanying files such as figures and tables can be submitted separately or as part of the main file. The manuscript file should be a Word document. Separate high resolution figures, supplemental material, or a supplemental video can also to be included with the submission. If the video is too large to submit, please contact jhd@iospress.com to arrange a file transfer. Further information about submitting supplementary data can be found below.

Resubmissions should include the manuscript number in the cover letter. The author's replies to the reviewer comments should be included within the revised manuscript itself (at the top). The revised paper should always be a Word document.

Article Publishing Charge
The Journal of Huntington's Disease does not charge an article publishing charge.

ETHICS POLICIES AND PATIENT PERMISSIONS

IOS Press has adopted Sage’s Publication ethics policies.  Please go to:  
Publication ethics and research integrity: policy guidelines for authors | SAGE Publications Ltd for details.

PREPARATION OF MANUSCRIPTS

Research Reports

Organization and style of presentation
1. Manuscripts must be written in English. Authors whose native language is not English are advised to consult a professional English language editing service or a native English speaker prior to submission.

2. Manuscripts should be double spaced throughout with wide margins (2.5cm or 1in), including the abstract and references. Every page of the manuscript, including the title page, references, tables, etc., should include a page number centered at the bottom.

3. Manuscripts should be organized in the following order with headings and subheadings typed on a separate line, without indentation.

Title page

  • Title (should be clear, descriptive and concise).
  • Full name(s) of author(s).
  • Full affiliation(s). Delineate affiliations with lowercase letters.
  • Present address of author(s), if different from affiliation.
  • Running title (45 characters or less, including spaces).
  • Complete correspondence address, including telephone number and email address.
  • Leave the author information blank if double-blind peer review is wished for, but do include the information in the cover letter.

Changes in Authorship

IOS Press has adopted Sage’s Authorship Policy.  Please go to:  Authorship guidelines | SAGE Publications Ltd for details.

Abstract and Keywords
-The abstract for research papers should follow the "structured abstract" format:
BACKGROUND: 
OBJECTIVE:
METHODS: 
RESULTS:
CONCLUSIONS:
The abstract should try to be no longer than 250 words.
- For other papers such as Reviews, the abstract should be clear, descriptive, and self-explanatory, and no longer than 250 words.
- Include a list of 4-10 keywords. These keywords should be terms from the MeSH database.

Introduction

Materials and Methods

Results

Discussion

Acknowledgments

Include individuals or companies which have assisted with your study, including advisors, administrative support and suppliers who may have donated or given materials used in the study.

If there are no acknowledgments, then do still include this section and insert: "The authors have no acknowledgments to report."

Funding

Include all funding sources for the study. If there is no funding involved, then do still include this section and insert: "The authors have no funding to report."

Conflict of Interest

All affiliations or financial involvement (e.g., employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, patents received or pending, royalties) with any organization or entity with a financial interest in, or in financial competition with, the subject matter or materials discussed in the manuscript must be disclosed in the submitted manuscript.

If there is no conflict of interest to declare, do still include this section and insert "The authors have no conflict of interest to report". If an author is also on the Editorial Board of this journal, the following statement should be included in this section: "<AUTHOR> is an Editorial Board member of this journal, but was not involved in the peer-review process nor had access to any information regarding its peer review.''

Datasets/Data Availability Statement (Required for Research Reports, Short Communications, and Systematic Reviews/Meta-Analyses)

All datasets and data articles cited in your manuscript should be included in the reference list of your article (not in a separate box or in the article text). Data references should include: author name(s), dataset title, data repository, version (where available), year, and identifier (DOI/URL/etc.). Authors should include a Data Availability statement at the end of the manuscript (before the References) to describe the availability or the absence of shared data. Authors are required to deposit sequence or proteomic data into a public repository (eg. GEO, Chorus) and include a link to the repository and data, and encouraged to publicly archive their research data including, but not limited to: software, algorithms, protocols, methods, and/or materials. Exceptions are made if sharing data compromises ethical standards or legal requirements.

Examples for your paper's "Data Availability" statement:

  1. The data supporting the findings of this study are openly available in [repository name] at [DOI and/or URL]. These data were derived from the following resources available in the public domain: [list resources and URLs].
  2. The data supporting the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
  3. The data supporting the findings of this study are available within the article and/or its supplementary material.
  4. Data sharing is not applicable to this article as no datasets were generated or analyzed during this study.

Artificial Intelligence Policy

Artificial intelligence (such as language models, machine learning systems, or similar technologies) cannot be authors of a manuscript. If these models or tools are used to produce content or aid in writing and manuscript preparation, the authors of the manuscript bear the responsibility for the quality and ethical standards of the generated content. Authors must acknowledge the utilization of these tools/technologies in the Methods section if integrated into formal research design or methods or if used for literature searches. If these tools/technologies are used to modify text written by the authors, this should be included in the Acknowledgment section. Authors must include details such as a description of the content created or modified, the name of the language model or tool, its version, extension numbers, and the manufacturer. Examples: "Approximately 15% of the text in this manuscript was generated with the assistance of ChatGPT, version [version number], a language model developed by OpenAI." or "ChatGPT, version [version number], a language model developed by OpenAI, was used for language refinement of this manuscript.

References
Authors are requested to use the Vancouver citation style. Place citations as numbers in square brackets in the text. All publications cited in the text should be presented in a list of references at the end of the manuscript. List the references in the order in which they appear in the text. Only articles published or accepted for publication should be listed in the reference list. We discourage textual references to unpublished and unavailable data. With permission, the author can reference a personal communication with name in the discussion section. If an article has a DOI, this should be provided after the page number details. The number is added after the letters 'doi'. Manuscripts will not be considered if they do not conform to the Vancouver citation guidelines.

References must be listed in Vancouver style:
[1] Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, et al. Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury. Brain Res. 2002;935(1-2):40-6.
[2] Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Medical microbiology. 4th ed. St. Louis: Mosby; 2002.
[3] Berkow R, Fletcher AJ, editors. The Merck manual of diagnosis and therapy. 16th ed. Rahway (NJ): Merck Research Laboratories; 1992.
[4] Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGrawHill; 2002. p. 93-113.
[5] Canadian Cancer Society [homepage on the Internet]. Toronto: The Society; 2006 [updated 2006 May 12; cited 2006 Oct 17]. Available from: www.cancer.ca/.
[6] Tian D, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. Proc Natl Acad Sci U S A. In press 2002.
[7] Fletcher D, Wagstaff CRD. Organisational psychology in elite sport: its emergence, application and future. Psychol Sport Exerc. 2009;10(4):427-34. doi:10.1016/j.psychsport.2009.03.009.

Tables
- Number according to their sequence in the text. The text should include references to all tables.
- Provide each table on a separate page of the manuscript after the references.
- Include a brief and self-explanatory title with any explanations essential to the understanding of the table given in footnotes at the bottom of the table.
- Vertical lines should not be used to separate columns. Leave some extra space between the columns instead.

Figure Legends

Figures
- Number the figures according to their sequence in the text. The text should include references to all figures.
- Figures should preferably be formatted in TIF or EPS format. JPG is also acceptable.
- A description of the statistical treatment of error analysis should be included in the figure or legend. We discourage the use of bar graphs where possible.
- Figures should be designed with the format of JHD in mind and preferable sized as they will appear when printed. A single column of the journal is 77mm and two columns are 165mm.
- Figures should be at 300 dpi or higher and be cropped to include the figure only (no blank space). CMYK is preferred for color figures.
- On figures where a scale is needed, use bar scales to avoid problems if the figure needs to be reduced.
- Each illustration should have a brief self-explanatory legend that should be typed separately from the figure in the section of the manuscript following the tables.
- Costs for color figures in the print version of the journal are as follows: 1 figure - 650 euro; 2 figures - 900 euro; 3 figures - 1050 euro; 4 figures - 1200 euro; 5 figures - 1350 euro. Cost for each additional color figure will be 150 euro. Color figures are free in the electronic version of the journal. You may opt to send in both black/white figures for print, and color figures for the online PDF (please adjust the figure legend appropriately).

Supplementary Material
Supplementary material can be submitted with the manuscript, included within the manuscript after the Figures and Tables (or otherwise after the References). Each supplementary item should have a legend and should not exceed the file size of 10MB. Supplemental videos can be submitted separately (see top of page for submission guidelines of videos). A short description of the supplementary items should be included under the header of “Supplementary Material” within the manuscript before the “References”. Supplementary material will be made available in the format in which it was provided. Large datasets should be hosted on the author’s own or institute’s website or in an appropriate database, and should be properly cited within the manuscript.

Review Articles
Reviews should be authoritative and topical and provide comprehensive and balanced coverage of a timely and/or controversial issue. Reviews should be prepared as detailed above for a Research Report, omitting Introduction through Discussion, and include a conclusion.

Short Communications
A short communication is an article of original scholarship of unusual interest of less than 1500 words (not including references). An abstract of 100 words or less should be included with no subdivison of text into sections. References should be formatted as above. A total of two tables and/or figures are allowed.

Hypotheses
A hypothesis article should be a balanced and insightful consideration of a topic with novel hypotheses well presented and supported. The article should be prepared as a Research Report but without Methods or Results sections.

Book Reviews
Book reviews should be 750 words or less and without sections. Suggestions can be proposed to the Editors-in-Chief.

Section: Inclusions in JHD
JHD Inclusions are brief commentaries written by the authors of recent high-impact papers in the field of HD research.

The JHD Editors will reach out to authors of highly significant publications to provide a short summary of their work. This can include additional insights or interpretations on the relevant topic. Potential authors for these Inclusion commentaries are welcome to also contact one of the Editors-in-Chief to inquire about the possibility of submitting to JHD.

The Inclusion commentary can include new data of relevance to the original paper including updating reported findings or additional data excluded from the original paper due to length restrictions. In addition we recommend adding a graphical description of the key findings of the original article.

There is no formal abstract (first paragraph should be a short summary and will be used as an abstract in pubmed) Total text length should be from 750 to 1500 words (limited to less than 1,500 words) with a maximum of 3 figures/tables. Word count does not including figure legends, which should be a maximum of 150 words for each figure. Inclusions can have up to 10 references but will need to have a very clear focus on the the original paper. Inclusions will be citable in punned.

Section: Controversies
This will be a section with Pro and Con commentaries on a specific topic of interest to the HD community. Each author will generate a short opinion piece which will have a maximum of 1000 to 2000 words (with one figure and max 15 references) to make the basic argument. Both sets of authors will receive a copy of both articles, and will be given two weeks to generate a short (200 word max.) rebuttal prior to publication. It is recommended that unsolicited authors email a proposal letter and formal academic outline of the discussion to the Editors (at jhd@iospress.com) to assess the topic, before submitting manuscripts.

Section: Correspondence
These are short letters to JHD that are either:

A). relating to a specific issue/case history in HD. Authors can submit commentaries or case reports of 1000 words or less for possible inclusion in the JHD. It is recommended that authors email a proposal letter and formal academic outline of the manuscript to the Editors (at jhd@iospress.com) to assess the topic, before submitting the full manuscript. Commentaries and case reports should include an abstract  (100 words max) but no other subdivisions, and should not include more than 15 references and one figure or table.

B). a response to a specific article published in JHD. Inclusion in JHD will be based on editorial decision and revision may be requested. Letters relating to a previous article will be shared with the authors of the original article for possible response prior to publication. Letters should not exceed 500 words (excluding references) and should not include more than 5 references and one figure or table. A letter can be signed by no more than three authors. Submit these to jhd@iospress.com.

REMEMBER TO INCLUDE

In the submission form:
- Name, postal address, phone number, and e-mail address of the corresponding author.
- Name of an Associate Editor with expertise in the area of the study (if no Associate Editor is suitable, the Editorial Office will handle the submission).
- Statement that all authors have contributed to the work, agree with the presented findings, and that the work has not been published before nor is being considered for publication in another journal.
- A list of at least 4-6 potential reviewers knowledgeable in the area of the study and potential reviewer conflicts.
- Statement that procedures involving experiments on human and animal subjects are done in accord with Publication ethics and research integrity: policy guidelines for authors | SAGE Publications Ltd.

In manuscript:
-
Compliance with guidelines on human and animal experimentation – for more details go here: Publication ethics and research integrity: policy guidelines for authors | SAGE Publications Ltd.
- Statement of all financial and material support for this research and any potential conflicts should also be clearly identified in the the acknowledgment and Conflict of Interest sections. If there is no Conflict-of-Interest then still add this statement.

Resubmissions
Resubmissions should include the manuscript number and a reference that the paper is a revision. The point-by-point response to the previous reviews should be included at the top of the manuscript. Please submit a tracked version of the paper so editors and reviewers can easily find the changes, or otherwise highlight the edited sections by color or by another detectable way.

PRE-PRESS AND PROOFS

The corresponding author will receive a pdf proof and is asked to check this proof carefully (the publisher will execute a cursory check only). Corrections other than printer's errors, however, should be avoided. Costs arising from such corrections will be charged to the authors. Please be sure to return your corrections as quickly as possible.

The corrected proofs will be placed in the online contents as a pre-press, and indexed in PubMed as "Epub ahead of print" article, after corrections are received from the authors. The pre-press article is fully citable by using the DOI number. This is not the final version. When the article is published in an issue, the final, updated version replaces the pre-press version.

Note: Any changes to authors or title after acceptance should also be sent to the editorial office (jhd@iospress.com) so our records can be updated.

IOS Press has adopted Sage’s Authorship Policy.  Please go to:  Authorship guidelines | SAGE Publications Ltd for details.

OPEN ACCESS MANDATES

A growing number of funding agencies now require that research articles they have funded must be made open access. This may be either by mandating deposit in repositories after an embargo period or by stipulating that research is published as open access. Publishing in this journal complies with all major funding agency requirements. Click here to discover about the IOS Press Open Library, and also to check if there are any institutional agreements that you might be eligible for.

Gold Open Access Publishing (Open Access Option)

The open access option helps authors to comply with major funder mandates. This option allows authors the choice of paying a fee to make their article publicly available on the journal’s website immediately upon publication. The publisher will also deposit the final, published version of the open access article into PubMed Central immediately upon publication. All open access articles are published under the terms of the Creative Commons Attribution Non-Commercial License.

If requested by the author, Research Councils UK (RCUK) and Wellcome Trust funded open access articles will be published under the terms of the Creative Commons Attribution License (CC BY).  An extra fee applies for CC BY publications.

Please click here to pay the open access fee.

Green Open Access Publishing (Self-Archiving)

Authors who do not select open access publication may self-archive and post the final manuscript version on their own institution, company, or funding agency repositories immediately upon acceptance. Authors that are funded by the NIH, Research Councils UK (RCUK) and Wellcome Trust are welcome to deposit their final manuscript version to PubMed Central (Submission Method C) and Europe PubMed Central immediately upon acceptance. In all cases a publication reference and URL to the journal’s website must be provided on the first page of the manuscript.

Alternatively, the author can submit the final published PDF version of the article, which can be ordered from IOS Press. This service costs €100/US$120 and an order form will be sent with the galley proof of the article to the corresponding author. Ordered PDFs will be sent to the author after final publication of the article in an issue. IOS Press holds to no embargo period after final publication. Orders for a PDF of published articles can also be sent to order@iospress.nl.

COPYRIGHT

Copyright of your article
Authors submitting a manuscript do so on the understanding that they have read and agreed to the terms of the IOS Press Author Copyright Agreement.

Article sharing
IOS Press adopted Sage’s Article Sharing Policy from 8th of July 2024. 
Please go to:  Sage’s Author Archiving and Re-Use Guidelines | SAGE Publications Ltd for details. If your manuscript was submitted prior to 8th of July 2024, please contact editorial@iospress.nl with details of your enquiry.

Quoting from Journal of Huntington’s Disease

Permissions for use of materials published in JHD Reports (figures, tables, thesis publication) can be requested at publisher@iospress.nl.

COMPLIMENTARY COPY AND PURCHASE

Complimentary copy
The corresponding author of a contribution to the journal is entitled to receive 1 author’s copy of the pdf free of charge, unless otherwise stated. Free copies will not be provided for conference proceedings and abstract issues.

How to order reprints, a pdf file, journals, or IOS Press books
An order form for reprints, additional journal copies or a non-watermarked pdf file will be provided along with the pdf proof.
If you wish to order reprints of an earlier published article, please contact the publisher for a quotation. IOS Press, Fax: +31 20 6870039. Email: editorial@iospress.nl.

An author is entitled to 25 % discount on IOS Press books. See Author's Discount (25%) on all IOS Press book publications.

KUDOS

Authors of published articles (non-prepress, final articles) will be contacted by Kudos. Kudos is a service that helps researchers maximize the impact and visibility of their research. It allows authors to enrich their articles with lay metadata, add links to related materials and promote their articles through the Kudos system to a wider public. Authors will receive no more than three emails: one invitation and a maximum of two reminders to register for the service and link the published article to their profile. Using and registering for Kudos remains entirely optional. For more information, please have a look at our authors section.

HOW TO PROMOTE YOUR WORK

Would you like some pointers on how to help your research achieve a wider reach and greater impact? Please consult our Promotional Toolkit for Authors for tips.

Please visit the IOS Press Authors page for further information.

Abstracted/Indexed in

Cabell's Guide or Directory
Chemical Abstracts Service (CAS)
Embase
MEDLINE
OA @ PubMedCentral
PubMed
PubsHub
Scopus

Web of Science: Emerging Sources Citation Index

Open Access

By default, articles published in the Journal of Huntington's Disease are available only to institutions and individuals with access rights. However, the journal offers all authors the option to purchase open access publication for their article as part of the IOS Press Open Library. This means that the final published version will be freely available to anyone worldwide, indefinitely, under a Creative Commons license and without the need to purchase access to the article. This is also referred to as “gold” open access.

Gold open access pricing
Authors who choose gold open access publication will be subject to an article publication charge of € 1500 / US$ 1500 for publication under the CC BY-NC 4.0 license or € 2150 / US$ 2150 for publication under the CC BY 4.0 license. Pricing is exclusive of possible taxes. After an article is accepted for publication, the corresponding author will be informed regarding the open access option during the production stages, and will have the opportunity to purchase open access for their article. It could be that the open access fee of an article is waived completely due an institutional agreement IOS Press has with the corresponding authors' institution. Please check the institutional agreements page for details.

Green open access
Authors who do not make use of the gold open access option may still make their article freely available using self-archiving, also referred to as green open access. Authors may make their final accepted manuscript available for free download from their personal or institutional website or institutional archive. This model is free for the author.

PubMedCentral deposits
This journal deposits all open access articles in PubMedCentral (PMC) as part of the IOS Press Open Library. If an author chooses to publish their paper with open access then the publisher will deposit the article in PMC upon publication.

Peer Review Policy

The Journal of Huntington’s Disease operates a rigorous, timely, blinded peer review process (with an option for double-blind if requested) by experts in the field. Please visit our reviewer guidelines for further information about how to conduct a review.

Manuscripts submitted to the journal will be assessed for suitability for publication in the journal by the Editors-in-Chief. Manuscripts that are deemed unsuitable may be rejected without peer review by the Editors-in-Chief and/or the Associate Editors, and the author will be informed as soon as possible.

Manuscripts that are deemed suitable for peer review are forwarded to an Associate Editor with expertise in that area who then recruits appropriate anonymous referees (a minimum of two) for confidential review. Referee reports are then assessed by the Associate Editor, who makes a decision which is then subject to approval by the Editors-in-Chief. Once approved this decision is then conveyed to the author along with the referees’ anonymized reports.

The initial decision will be one of the following: rejection, acceptance without revision, or potentially acceptable after minor or major revisions. Revised manuscripts will be appraised by the Associate Editor, who may seek the opinion of referees (prior or new) before making a decision, which again is subject to approval of the Editors-in-Chief. Once approved, this decision is then conveyed to the author along with the anonymized referees’ reports. Once accepted, manuscripts are normally published on-line without delay and appear in the next available print issue (published quarterly).

The Editors-in-Chief have ultimate responsibility for what is published in the journal. Authors may appeal decisions by contacting the Editors-in-Chief (at jhd@iospress.com). Authors will be informed in writing of the result of their appeal.

Special Issue on Sleep and Circadian Rhythms in Huntington’s Disease
Discover the fascinating connection between sleep and Huntington's disease in our latest Special Issue of the Journal of Huntington's Disease (JHD).Dive into a collection of meticulously curated articles that unveil the intricate relationship between neurodegeneration and sleep patterns. 

Impact Factor
In 2023 the Journal of Huntington’s Disease received its first impact factor of 3.1 (Clarivate’s Journal Citation Report: Emerging Sources Citation Index). This represents an impressive first number for this quality and highly specialized publication. The annual JCR release enables the research and library communities to evaluate the world's high-quality academic journals using a range of journal citation indicators, descriptive data and visualizations.

Social Media & Sign Ups: The Journal of Huntington's Disease (JHD) is on Facebook and Twitter, with social media editor Tamara Maiuri at the helm. Be sure to follow us and be part of the conversation! If you do not already receive the JHD newsletter, we invite you to sign up to receive notification of new JHD issues, plus other related news. Sign up via this link tiny.cc/JHDsignup & you can read the latest newsletter here.

10th Anniversary: Discover the editorial by the Editors-in-Chief Blair R. Leavitt, MD, and Leslie M. Thompson, PhD, on the journal's first 10 years, published in the first issue of 2022 (in Vol.11, Iss.1). More insights and highlights are included on our celebratory 10th anniversary page here!

Clinical Trials Corner: This open-access feature was launched in 2017 (JHD 6:3, Sept 2017), with Drs. Edward Wild and Filipe Rodrigues as editors of this section. Read the first instalment here – one of the top 10 most viewed JHD articles of 2017. If you know of any Huntington's Disease Clinical Trials that have not been featured, feel free to get in touch with Dr. Wild by email

Indexing: JHD is included in PubMed (MEDLINE), the largest component of PubMed. MEDLINE is searchable for free using PubMed at pubmed.gov. Citations and abstracts for articles published in JHD are listed going back to Volume 1/Number 1.

Latest Articles

Discover the contents of the latest journal issue:

Huntington’s Disease Clinical Trials Corner: March 2024
Sarah J. Tabrizi, Carlos Estevez-Fraga, Edward J. Wild

Theory of Mind in Huntington’s Disease: A Systematic Review of 20 Years of Research
Wilmar Pineda-Alhucema, Johana Escudero-Cabarcas, Martha Martinez-Banfi, Johan E. Acosta-López, Martha L. Cervantes-Henriquez, Elsy Mejía-Segura, Giomar Jiménez-Figueroa, Cristian Sánchez-Barros, Pedro J. Puentes-Rozo, Luz M. Noguera-Machacón, Mostapha Ahmad, Moisés de la Hoz, Jorge I. Vélez, Mauricio Arcos-Burgos, David A. Pineda, Manuel Sánchez

Somatic CAG Repeat Stability in a Transgenic Sheep Model of Huntington’s Disease
Suzanne J. Reid, Renee R. Handley, Zoe Burch, Jessie C. Jacobsen, Tammy Gillis, Kevin Correia, Skye R. Rudiger, Clive J. McLaughlin, C. Simon Bawden, Marcy E. MacDonald, Vanessa C. Wheeler, Russell G. Snell

Mono- and Biallelic Inactivation of Huntingtin Gene in Patient-Specific Induced Pluripotent Stem Cells Reveal HTT Roles in Striatal Development and Neuronal Functions
Michel Cailleret, Morgane Louessard, Margot Jarrige, Julie Bigarreau, Sophie Lenoir, Noëlle Dufour, Maria Rey, Frédéric Saudou, Nicole Deglon, Anselme L. Perrier

Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington’s Disease-Like Symptoms in Rats
Azzam F. Azzam, Russell G. Wells, Amie L. Hiller, Michael F. Sardinia

Sustainable Development Goals

The content of this journal relates to SDG:

sdg symbolsdg symbol

Visit the SDG page for more information.

Supporting Diversity and Inclusion

This journal supports IOS Press' actions relating to the Sustainable Development Goals (SDGs) and commits to the Diversity and Inclusion Statement.

dark blue banner for JHD author geo data for SDGs

More information will be available in due course. Check the SDGs page for updates.

JHD clinical trials corner visual

cony